Julie Carpenter, MD
Family Medicine · Southaven, MSNPI 1497757520
Payments from drug & device makers
Across 375 payments — averaging $13.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$754
- Novo Nordisk$685
- AbbVie$560
- Lilly USA, LLC$502
- Amarin Pharma, Inc.$478
- Merck$267
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,992100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 53 | $754 |
| Novo Nordisk | 51 | $685 |
| AbbVie(2 entities) | 43 | $560 |
| Lilly USA, LLC | 45 | $502 |
| Amarin Pharma, Inc. | 28 | $478 |
| Merck | 22 | $267 |
| Boehringer Ingelheim | 17 | $251 |
| Pfizer | 17 | $184 |
| Amgen | 14 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $155 |
| Kowa Pharmaceuticals America, Inc. | 15 | $109 |
| Bayer | 6 | $108 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Esperion Therapeutics, Inc. | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 5 | $60 |
| Astellas Pharma US Inc | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $53 |
| GSK | 4 | $51 |
| Genentech USA, Inc. | 3 | $38 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Electromed, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 3 | $35 |
| Shire North American Group Inc | 3 | $35 |
| Assertio Therapeutics, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 2 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $18 |
| Nevro Corp. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $13 |
| Abbott | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$100
How this compares
$5,004 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $39,684 |
| MounjaroTirzepatide | 27 | $38,183 |
| OzempicSemaglutide | 30 | $35,150 |
| XareltoRivaroxaban | 19 | $27,970 |
| FarxigaDapagliflozin Propanediol | 26 | $27,603 |
| EliquisApixaban | 27 | $27,404 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $27,279 |
| TradjentaLinagliptin | 20 | $22,692 |
| LinzessLinaclotide | 24 | $20,015 |
| JanuviaSitagliptin Phosphate | 12 | $12,097 |
| EntrestoSacubitril/Valsartan | 12 | $11,093 |
| MyrbetriqMirabegron | 23 | $10,882 |
| VascepaIcosapent Ethyl | 12 | $6,812 |
| Nebivolol Hcl | 22 | $3,700 |
| Gabapentin | 117 | $2,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $251 | $62,37651 claims |
| Lilly USA, LLCMounjaro | $502 | $38,18327 claims |
| Novo NordiskOzempic | $685 | $35,15030 claims |
| Johnson & JohnsonXarelto | $12 | $27,97019 claims |
| AstraZenecaFarxiga | $754 | $27,60326 claims |
| PfizerEliquis | $184 | $27,40427 claims |
| GSKTrelegy Ellipta | $51 | $27,27922 claims |
| AbbVieLinzess | $560 | $20,01524 claims |
| MerckJanuvia | $267 | $12,09712 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $10,88223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Southaven
- Walter CarnahanSouthaven$146K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.